Cetuximab and panitumumab are monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), approved in multiple countries, including the U.S., Canada, and the EU, for the treatment of head and neck squamous cell carcinoma (HNSCC—cetuximab) and colorectal cancer (CRC—cetuximab and panitumumab) [53]. Here, EGFR is linked to colorectal carcinoma.